The delays have nothing to do with this issue. You and he both understand the real situation, yet you continue posting here as if you’re “invested,” despite having an entire financial world to choose from. That is what makes no sense. No one trashes their own investment and its shareholders expecting the price to rise.
As for “executive experience,” that has nothing to do with the basic need for authorized shares to keep a prerevenue company solvent. The choice here is straightforward and rational, and the company’s leadership has far more experience than the people criticizing them.
When a company exhausts its authorized shares, it destroys shareholder value—full stop. Anyone arguing that a prerevenue biotech should somehow operate without the ability to raise capital is not acting in shareholders’ interests. These narratives almost always come from vulture investors who try to herd retail investors into voting against their own interests using emotional, misleading arguments.
And that is exactly what we’re seeing right now: an attempt to push retail into a fundamentally destructive vote because destroying companies is easy profit for vultures.
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
AI
